Cargando…

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p

We analyzed 44 patients with newly diagnosed systemic light-chain amyloidosis (AL) and del 17p, a rare finding in AL. Predictors of overall and progression-free survival were cardiac involvement at diagnosis and hematologic response to therapy, respectively. Median survivals of patients with > 50...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Sandy W., Hegenbart, Ute, Palladini, Giovanni, Shah, Gunjan L., Landau, Heather J., Warner, Melissa, Toskic, Denis, Jaccard, Arnaud, Hansen, Timon, Bladé, Joan, Cibeira, M. Teresa, Kastritis, Efstathios, Dispenzieri, Angela, Wechalekar, Ashutosh, Varga, Cindy, Schönland, Stefan O., Comenzo, Raymond L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441584/ https://www.ncbi.nlm.nih.gov/pubmed/30104177 http://dx.doi.org/10.1016/j.clml.2018.07.292

Ejemplares similares

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2021)

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
por: Jaccard, A., et al.
Publicado: (2022)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
por: Gertz, M., et al.
Publicado: (2023)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Deferred autologous stem cell transplantation in systemic AL amyloidosis
por: Manwani, Richa, et al.
Publicado: (2018)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
por: Havasi, Andrea, et al.
Publicado: (2022)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

The Evolving Epidemiology of Amyloidosis
por: Wechalekar, Ashutosh D.
Publicado: (2021)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2021)

Extensive cardiac FDG uptake in a patient with AL amyloidosis
por: Hatipoglu, Suzan, et al.
Publicado: (2023)

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
por: Lisenko, Katharina, et al.
Publicado: (2016)

Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021)

A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis
por: Fu, Julie, et al.
Publicado: (2019)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2019)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
por: Ma, Xun, et al.
Publicado: (2018)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: Minnema, Monique, et al.
Publicado: (2023)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r6ufibrl6pnf38dkvncn8eijit